cd138 enriched cells Search Results


cd138+ cell enrichment of bma  (LabCorp)
90
LabCorp cd138+ cell enrichment of bma
Analysis of baseline immune and tumor characteristics of subjects enrolled in cohorts A, B, and D of the CC-220-MM-001 study (A) Dot plot of absolute (ABS) cells per μL in peripheral blood of subjects on cycle 1 day 1 (C1D1) for monocytes (CD14 + ), B cells (CD3 − CD19 + ), NK cells (CD3 − CD56 + /CD16 + ), T cells (CD3 + ), CD4 + T cells (CD3 + CD4 + ), and CD8 + T cells (CD3 + CD8 + ). Each dot represents one subject, the red line represents the median, and the gray box represents normal laboratory ranges for each assessment. (B) Dot plot of proportion of cells from indicated lineage positive for phenotypic markers for subjects on C1D1, including proportions of NK and T cells proliferating (Ki-67 + ), CD4 + T cells and CD8 + T cells activated (HLA-DR + or ICOS + ), CD4 + T cells and CD8 + T cells in naive state (CD45RO − CCR7 + ), CD4 + T cells and CD8 + T cells in central memory (CM) state (CD45RO + CCR7 + ), and CD4 + T cells and CD8 + T cells in effector memory (EM) state (CD45RO + CCR7 − ). Each dot represents one subject, and the red line represents the median. (C) Dot plot of proportion of cells from indicated lineage positive for exhaustion markers for subjects on C1D1, including proportion of CD4 + and CD8 + T cells expressing LAG-3 (CD223), PD-1 (CD279), and Tim-3 (CD366) and proportion of CD4 + Tregs (CD25 + CD127 − /loFoxP3 + ). Each dot represents one subject, and the red line represents the median. (D) Box and whisker plots of <t>CD138</t> + involved H-score for total CRBN expression and nuclear Aiolos expression in indicated patient subsets. Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent the minimum and maximum. Data are shown for patients who had lenalidomide or pomalidomide (POM) in their last line (Len last, Pom last), who were refractory to Pom (Pom R), who were triple-class refractory (defined as refractory to ≥1 immunomodulatory agent, ≥1 proteasome inhibitor, and ≥1 anti-CD38 antibody), or who were fifth line or later (5L+). (E) Oncoplot of most prevalent mutations (green), copy-number aberrations (blue) and translocations (orange), or CRBN dysregulation (CRBN mutation, CRBN loss of heterozygosity, high expression of CRBN-del-exon10 , or 2q [COPS7b/COPS8] deletion) at baseline in patients who had whole-genome sequencing (WGS) and RNA sequencing (RNA-seq) data available. Prevalence is shown on left y axis and is limited to aberrations present in ≥3% of patients (note that there were no aberrations present at 3%, so the plot shows 4% and above). High Del10 = high expression of the CRBN-del-exon10 transcript.
Cd138+ Cell Enrichment Of Bma, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd138+enriched+cells/cd138++cell+enrichment+of+bma/pmc11228401-37-0-6
Average 90 stars, based on 1 article reviews
cd138+ cell enrichment of bma - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Analysis of baseline immune and tumor characteristics of subjects enrolled in cohorts A, B, and D of the CC-220-MM-001 study (A) Dot plot of absolute (ABS) cells per μL in peripheral blood of subjects on cycle 1 day 1 (C1D1) for monocytes (CD14 + ), B cells (CD3 − CD19 + ), NK cells (CD3 − CD56 + /CD16 + ), T cells (CD3 + ), CD4 + T cells (CD3 + CD4 + ), and CD8 + T cells (CD3 + CD8 + ). Each dot represents one subject, the red line represents the median, and the gray box represents normal laboratory ranges for each assessment. (B) Dot plot of proportion of cells from indicated lineage positive for phenotypic markers for subjects on C1D1, including proportions of NK and T cells proliferating (Ki-67 + ), CD4 + T cells and CD8 + T cells activated (HLA-DR + or ICOS + ), CD4 + T cells and CD8 + T cells in naive state (CD45RO − CCR7 + ), CD4 + T cells and CD8 + T cells in central memory (CM) state (CD45RO + CCR7 + ), and CD4 + T cells and CD8 + T cells in effector memory (EM) state (CD45RO + CCR7 − ). Each dot represents one subject, and the red line represents the median. (C) Dot plot of proportion of cells from indicated lineage positive for exhaustion markers for subjects on C1D1, including proportion of CD4 + and CD8 + T cells expressing LAG-3 (CD223), PD-1 (CD279), and Tim-3 (CD366) and proportion of CD4 + Tregs (CD25 + CD127 − /loFoxP3 + ). Each dot represents one subject, and the red line represents the median. (D) Box and whisker plots of CD138 + involved H-score for total CRBN expression and nuclear Aiolos expression in indicated patient subsets. Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent the minimum and maximum. Data are shown for patients who had lenalidomide or pomalidomide (POM) in their last line (Len last, Pom last), who were refractory to Pom (Pom R), who were triple-class refractory (defined as refractory to ≥1 immunomodulatory agent, ≥1 proteasome inhibitor, and ≥1 anti-CD38 antibody), or who were fifth line or later (5L+). (E) Oncoplot of most prevalent mutations (green), copy-number aberrations (blue) and translocations (orange), or CRBN dysregulation (CRBN mutation, CRBN loss of heterozygosity, high expression of CRBN-del-exon10 , or 2q [COPS7b/COPS8] deletion) at baseline in patients who had whole-genome sequencing (WGS) and RNA sequencing (RNA-seq) data available. Prevalence is shown on left y axis and is limited to aberrations present in ≥3% of patients (note that there were no aberrations present at 3%, so the plot shows 4% and above). High Del10 = high expression of the CRBN-del-exon10 transcript.

Journal: Cell Reports Medicine

Article Title: Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

doi: 10.1016/j.xcrm.2024.101571

Figure Lengend Snippet: Analysis of baseline immune and tumor characteristics of subjects enrolled in cohorts A, B, and D of the CC-220-MM-001 study (A) Dot plot of absolute (ABS) cells per μL in peripheral blood of subjects on cycle 1 day 1 (C1D1) for monocytes (CD14 + ), B cells (CD3 − CD19 + ), NK cells (CD3 − CD56 + /CD16 + ), T cells (CD3 + ), CD4 + T cells (CD3 + CD4 + ), and CD8 + T cells (CD3 + CD8 + ). Each dot represents one subject, the red line represents the median, and the gray box represents normal laboratory ranges for each assessment. (B) Dot plot of proportion of cells from indicated lineage positive for phenotypic markers for subjects on C1D1, including proportions of NK and T cells proliferating (Ki-67 + ), CD4 + T cells and CD8 + T cells activated (HLA-DR + or ICOS + ), CD4 + T cells and CD8 + T cells in naive state (CD45RO − CCR7 + ), CD4 + T cells and CD8 + T cells in central memory (CM) state (CD45RO + CCR7 + ), and CD4 + T cells and CD8 + T cells in effector memory (EM) state (CD45RO + CCR7 − ). Each dot represents one subject, and the red line represents the median. (C) Dot plot of proportion of cells from indicated lineage positive for exhaustion markers for subjects on C1D1, including proportion of CD4 + and CD8 + T cells expressing LAG-3 (CD223), PD-1 (CD279), and Tim-3 (CD366) and proportion of CD4 + Tregs (CD25 + CD127 − /loFoxP3 + ). Each dot represents one subject, and the red line represents the median. (D) Box and whisker plots of CD138 + involved H-score for total CRBN expression and nuclear Aiolos expression in indicated patient subsets. Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent the minimum and maximum. Data are shown for patients who had lenalidomide or pomalidomide (POM) in their last line (Len last, Pom last), who were refractory to Pom (Pom R), who were triple-class refractory (defined as refractory to ≥1 immunomodulatory agent, ≥1 proteasome inhibitor, and ≥1 anti-CD38 antibody), or who were fifth line or later (5L+). (E) Oncoplot of most prevalent mutations (green), copy-number aberrations (blue) and translocations (orange), or CRBN dysregulation (CRBN mutation, CRBN loss of heterozygosity, high expression of CRBN-del-exon10 , or 2q [COPS7b/COPS8] deletion) at baseline in patients who had whole-genome sequencing (WGS) and RNA sequencing (RNA-seq) data available. Prevalence is shown on left y axis and is limited to aberrations present in ≥3% of patients (note that there were no aberrations present at 3%, so the plot shows 4% and above). High Del10 = high expression of the CRBN-del-exon10 transcript.

Article Snippet: CD138+ cell enrichment of BMA , Labcorp , NSSO6495_10936.

Techniques: Expressing, Whisker Assay, Mutagenesis, Sequencing, RNA Sequencing

Iberdomide immune pharmacodynamic effects Longitudinal analysis of iberdomide-induced changes in immune cell subsets. (A) Line graph of median percentage of change with standard error in ABS B cell (CD3 − CD19 + ) counts from patients treated with iberdomide+dexamethasone in cohorts B and D. (B) Box and whisker plots showing proportion of proliferating NK cells (CD3 − CD56/CD16 + %Ki67 + ) (left) and proportion of proliferating T cells (CD3 + %Ki-67 + ) (right) by enrollment dose group and cohort. Adjacent doses with overlapping exposure were combined. The middle line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent 95% confidence interval (CI). (C) Line graph of median percentage of change with standard error in proportion of CD4 + T cells in naive phenotype (CD45RO − CCR7 + ) (left), in CM phenotype (CD45RO + CCR7 + ) (middle), and in EM phenotype (CD45RO + CCR7 − ) (right) by enrollment dose group counts from patients treated with iberdomide+dexamethasone in cohorts B and D. Adjacent doses with overlapping exposure were combined. Red arrows indicate the peak of iberdomide induction of activated/EM state by mid-cycle 2/4 after 2 weeks of dosing, and blue arrows indicate changes after a 1 week drug holiday. (D) Box and whisker plots of percentage of change from C1D1 to C2D15 for patients dosed above 0.75 mg with iberdomide+dexamethasone in cohorts B and D in proportion of CD4 + (green) and CD8 + (blue) T cells positive (left) and median fluorescence intensity (right) for activation marker HLA-DR. Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent 95% CI. (E) Box and whisker plots of percentage of change from C1D1 to C2D15 for patients dosed above 0.75 mg with iberdomide+dexamethasone in cohorts B and D in proportion of cells from indicated phenotypic markers who were naive to POM (blue) or directly post-POM (orange) (patients with POM as a last line of therapy <3 months prior to enrollment). Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent 95% CI. (F) Granzyme B levels in bone marrow aspirate plasma at screening and C2D15.

Journal: Cell Reports Medicine

Article Title: Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

doi: 10.1016/j.xcrm.2024.101571

Figure Lengend Snippet: Iberdomide immune pharmacodynamic effects Longitudinal analysis of iberdomide-induced changes in immune cell subsets. (A) Line graph of median percentage of change with standard error in ABS B cell (CD3 − CD19 + ) counts from patients treated with iberdomide+dexamethasone in cohorts B and D. (B) Box and whisker plots showing proportion of proliferating NK cells (CD3 − CD56/CD16 + %Ki67 + ) (left) and proportion of proliferating T cells (CD3 + %Ki-67 + ) (right) by enrollment dose group and cohort. Adjacent doses with overlapping exposure were combined. The middle line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent 95% confidence interval (CI). (C) Line graph of median percentage of change with standard error in proportion of CD4 + T cells in naive phenotype (CD45RO − CCR7 + ) (left), in CM phenotype (CD45RO + CCR7 + ) (middle), and in EM phenotype (CD45RO + CCR7 − ) (right) by enrollment dose group counts from patients treated with iberdomide+dexamethasone in cohorts B and D. Adjacent doses with overlapping exposure were combined. Red arrows indicate the peak of iberdomide induction of activated/EM state by mid-cycle 2/4 after 2 weeks of dosing, and blue arrows indicate changes after a 1 week drug holiday. (D) Box and whisker plots of percentage of change from C1D1 to C2D15 for patients dosed above 0.75 mg with iberdomide+dexamethasone in cohorts B and D in proportion of CD4 + (green) and CD8 + (blue) T cells positive (left) and median fluorescence intensity (right) for activation marker HLA-DR. Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent 95% CI. (E) Box and whisker plots of percentage of change from C1D1 to C2D15 for patients dosed above 0.75 mg with iberdomide+dexamethasone in cohorts B and D in proportion of cells from indicated phenotypic markers who were naive to POM (blue) or directly post-POM (orange) (patients with POM as a last line of therapy <3 months prior to enrollment). Each dot represents a single patient value, the line represents the median, the top and bottom of the box represent the 25 th and 75 th percentiles, respectively, and whiskers represent 95% CI. (F) Granzyme B levels in bone marrow aspirate plasma at screening and C2D15.

Article Snippet: CD138+ cell enrichment of BMA , Labcorp , NSSO6495_10936.

Techniques: Whisker Assay, Fluorescence, Activation Assay, Marker, Clinical Proteomics

Journal: Cell Reports Medicine

Article Title: Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

doi: 10.1016/j.xcrm.2024.101571

Figure Lengend Snippet:

Article Snippet: CD138+ cell enrichment of BMA , Labcorp , NSSO6495_10936.

Techniques: Extraction, Flow Cytometry, Clinical Proteomics, Software